Match!
Teresa Casals Galobart
The Royal Marsden NHS Foundation Trust
CellMonocarboxylate transporter 1MitochondrionMedicineCancer cell
3Publications
2H-index
13Citations
What is this?
Publications 5
Newest
#1Mounia Beloueche-Babari (The Royal Marsden NHS Foundation Trust)H-Index: 12
#2Teresa Casals Galobart (The Royal Marsden NHS Foundation Trust)H-Index: 2
Last. Martin O. Leach (The Royal Marsden NHS Foundation Trust)H-Index: 70
view all 8 authors...
Monocarboxylate transporter 1 (MCT1) is a regulator of cell metabolism and a therapeutic target for cancer treatment. Understanding the changes in tumour function accompanying MCT1 inhibition will better characterise the anti-tumour effects of MCT1 inhibitors, potentially enabling the identification of pharmacodynamic biomarkers for the clinical development of these agents. We assessed the impact of the MCT1 inhibitor AZD3965 on tumour metabolism and immune cell infiltration as key determinants ...
Source
#1Teresa Delgado-Goñi (University of Oxford)H-Index: 1
#2Teresa Casals Galobart (The Royal Marsden NHS Foundation Trust)H-Index: 2
Last. Mounia Beloueche-Babari (The Royal Marsden NHS Foundation Trust)H-Index: 12
view all 7 authors...
BRAF inhibitors, such as vemurafenib, have shown efficacy in BRAF-mutant melanoma treatment but acquired-resistance invariably develops. Unveiling the potential vulnerabilities associated with vemurafenib resistance could provide rational strategies for combinatorial treatment. This work investigates the metabolic characteristics and vulnerabilities of acquired resistance to vemurafenib in three generated BRAF-mutant human melanoma cell clones, analysing metabolic profiles, gene and protein expr...
1 CitationsSource
#1Mounia Beloueche-Babari (The Royal Marsden NHS Foundation Trust)H-Index: 12
#2Slawomir Wantuch (The Royal Marsden NHS Foundation Trust)H-Index: 2
Last. Martin O. Leach (The Royal Marsden NHS Foundation Trust)H-Index: 70
view all 10 authors...
Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify pharmacodynamic biomarkers to support the clinical development of MCT inhibitors now in clinical trials. In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism in vitro and in vivo . Exposing human lymphoma and colo...
11 CitationsSource
#1Anant Shah (The Royal Marsden NHS Foundation Trust)H-Index: 3
#2Teresa Delgado-Goñi (The Royal Marsden NHS Foundation Trust)H-Index: 7
Last. Mounia Beloueche-Babari (The Royal Marsden NHS Foundation Trust)H-Index: 12
view all 9 authors...
Targeted therapies specific to the BRAF-MEK-ERK signaling pathway have shown great promise in the treatment of malignant melanoma in the last few years, with these drugs now commonly used in clinic. Melanoma cells treated using these agents are known to exhibit increased levels of melanin pigment and tyrosinase activity. In this study we assessed the potential of non-invasive imaging approaches (photoacoustic imaging (PAI) and magnetic resonance imaging (MRI)) to detect melanin induction in SKME...
2 CitationsSource
Last. Martin O. LeachH-Index: 70
view all 5 authors...
Source
1